Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![cenmag Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::106542267.png) C&EN (Chemical & Engineering News) [@cenmag](/creator/twitter/cenmag) on x 125.4K followers
Created: 2025-06-13 18:30:20 UTC

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1933592793072488456/c:line.svg)

**Related Topics**
[$ryzb](/topic/$ryzb)
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/cenmag/status/1933592793072488456)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

cenmag Avatar C&EN (Chemical & Engineering News) @cenmag on x 125.4K followers Created: 2025-06-13 18:30:20 UTC

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem.

XXXXX engagements

Engagements Line Chart

Related Topics $ryzb $bmy stocks healthcare

Post Link

post/tweet::1933592793072488456
/post/tweet::1933592793072488456